Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Response crawled time : 20:20 save search
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Published: 2024-04-07 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 2.24%
H: 0.0%
C: -0.8%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.11%
H: 0.32%
C: -0.07%
response
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
Published: 2024-04-07 (Crawled : 20:20) - globenewswire.com
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 1.38%
H: 0.2%
C: -1.27%
candidate cancer pancreatic tumor immunotherapy for response show
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
Published: 2023-12-09 (Crawled : 20:20) - prnewswire.com
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
| Email alert
Add to watchlist
CERE | News | $42.16 1.35% 1.33% 1.3M
|
Finance
| Email alert
Add to watchlist
GNMSF | $281.02 3.83% 210
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
cd20 duobody antibody treatment response
Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Published: 2023-07-29 (Crawled : 20:20) - prnewswire.com
CTXR | $0.8 -1.99% -2.02% 6.3M
|
Health Technology
| Email alert
Add to watchlist
drug t-cell food treatment response
Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma
Published: 2023-06-03 (Crawled : 20:20) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
response results study
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma
Published: 2023-06-03 (Crawled : 20:20) - prnewswire.com
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | $281.02 3.83% 210
|
Health Technology
| Email alert
Add to watchlist
response
Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial
Published: 2023-05-21 (Crawled : 20:20) - globenewswire.com
IMMX | News | $2.25 -10.0% -11.11% 190K
|
|
| O: 17.68%
H: 0.0%
C: -9.33%
nxc-201 positive biopharma ongoing trial response results
Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives
Published: 2023-01-08 (Crawled : 20:20) - globenewswire.com
VIRX | $0.8971 -4.18% -4.36% 79K
|
Manufacturing
|
| O: 17.07%
H: 8.33%
C: 5.21%
tumor therapeutics response
Verisk’s Geospatial Data, AI-Enhanced Analytics and Vexcel’s Aerial Imagery Combine to Help Accelerate Insurance Response to Historic Hurricane Damage
Published: 2022-10-01 (Crawled : 20:20) - globenewswire.com
VRSK | $223.31 0.48% 0.47% 680K
|
Finance
| Email alert
Add to watchlist
analytics insurance response
Verizon Response: unlimited call/text/data for parts of Kentucky, Illinois
Published: 2021-12-12 (Crawled : 20:20) - globenewswire.com
VZ | News A | $40.13 0.88% -0.08% 18M
|
Communications
|
| O: -0.34%
H: 0.0%
C: 0.0%
response
Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
Published: 2021-12-11 (Crawled : 20:20) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
| Email alert
Add to watchlist
kymriah novartis risk response
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.